In contrast, the cells of RUNX1-deficient chimeric mice can also develop T-cell lymphoma after treatment with ENU, suggesting that the loss of RUNX1 activity may also lead to lymphoid malignancies [45]. This evidence concerns the gene RUNX1 and T-cell non-Hodgkin lymphoma.